A Study of MEDI9253 in combination with durvalumab in select solid tumors

Trial Identifier: D7880C00001
Sponsor: AstraZeneca
Start Date: December 2020
Primary Completion Date: May 2024
Study Completion Date: May 2024
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
French Translation

Trial Locations

Country Location
FR Bordeaux, FR, 33076
FR Toulouse, FR, 31100
FR Villejuif, FR, 94800
US, MO Saint Louis, MO, US, 63110
US, NY Buffalo, NY, US, 14263
US, NY New York, NY, US, 10032
US, NY New York, NY, US, 10065
US, PA Pittsburgh, PA, US, 15232